MedDataX Logo

Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome

NCT ID: NCT00557414

Last Updated: 2008-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

63 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-10-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the impact of the serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) on etiology and prognosis of acute respiratory distress syndrome (ARDS)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, is upregulated on phagocytic cells in the presence of bacteria or fungi infection and weakly expressed in samples from patients with noninfectious inflammatory disorders. In addition, TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form (sTREM-1) in body fluids. The level and serial change of a serum sTREM-1 from cirtical ill patients has been shown to be a good diagnostic and prognostic indicator of ventilation associated pneumonia (VAP) and severe sepsis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

acute respiratory distress syndrome soluble triggering receptor expressed on myeloid cells-1 prognosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Fulfill clinical diagnosis of ARDS
* Require mechanical ventilation support

Exclusion Criteria

* Pregnant
* Immunocompromised
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Taiwan University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

National Taiwan University Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chao-Chi Ho

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine and Emergency Medicine, National Taiwan University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

200709060R

Identifier Type: -

Identifier Source: org_study_id